-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
We revise our 12-month target to $90 from $100, following IR's Q1 earnings release, valuing shares at 23x our 2027 EPS outlook of $3.93 (down from $3.97; 2026 EPS estimate unchanged), near IR's long-term historical forward average and peer multiples. While IR's adjusted EPS of $0.77 (+7% Y/Y) beat expectations, the underlying results revealed a challenging quarter for organic sales and order growth. Total revenue grew 8% on acquisitions and FX, but organic revenue dipped 0.3%, reflecting a sharp divergence between the company's two segments. The Precision & Science Tech segment performed strongly, with 4% organic growth and margin expansion, while the larger Industrial Tech segment faced a 2% sales decline and 210 bps of margin compression from volume and tariff headwinds. 2026 earnings guidance is back-half weighted, which we see carrying execution risk, as there is little margin for error. Looking ahead, Q3 will be a critical quarter for IR as a broader recovery is expected to gain traction.